EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies

Fatma Al Jasmi, Zhanna Belaya

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0227 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Fatma Al Jasmi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics & Genomics, College of Medicine & Health Science, United Arab Emirates University, Al Ain, UAE. Hauptthemen laut MEDLINE: Hypophosphatasia, Recombinant Fusion Proteins, Alkaline Phosphatase, Immunoglobulin G. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What is this summary about? Hypophosphatasia (HPP for short) is a rare inherited condition that can present at any stage of life, with symptoms typically being more severe in cases that manifest earlier, such as during infancy or childhood. This article summarizes three published studies that looked at the safety and effectiveness of asfotase alfa for people with HPP. The aim of this article is to present the findings of three studies clearly and engagingly to make them accessible to readers without a scientific background. The first study (called study 1) discussed in this article looked at how safe and effective asfotase alfa was for children with life-threatening HPP. The second study (called study 2) looked at how safe and effective asfotase alfa was for children or adolescents who had showed the first signs of HPP at birth or in childhood. They received treatment in clinical practice in Japan, rather than in a clinical research study. The third study (called study 3) looked at how safe and effective asfotase alfa was for adults with HPP who had showed the first signs of the condition in childhood. They received treatment in clinical practice, rather than in a clinical research study. What were the results? In study 1, asfotase alfa improved bone health, the ability to breathe, and growth in children with life-threatening HPP. The researchers saw these benefits over 6 years of follow-up by HPP care teams. The treatment was generally well-tolerated. In study 2, asfotase alfa relieved symptoms such as pain, improved growth, and improved the ability to breathe in children and adolescents with HPP in Japan. The treatment was generally well-tolerated, with no serious side effects. Some participants had mild reactions at injection sites. In study 3, asfotase alfa improved physical function and quality of life for adults with HPP. People were able to walk further and faster and had improved grip strength. The researchers saw these benefits as early as 3 months, and they continued over 2 years. The treatment was welltolerated. Some people had mild reactions at injection sites. What do the results of the studies mean? The combined results from these studies indicate that asfotase alfa is effective and safe to treat people with HPP of different ages and levels of symptom severity. Asfotase alfa improves bone health, mobility, growth, and breathing ability, and relieves pain. Treatment can improve quality of life for people with HPP. The findings from these studies support the continued use and further development of asfotase alfa as a treatment for people with HPP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypophosphatasiaRecombinant Fusion ProteinsAlkaline PhosphataseImmunoglobulin GEnzyme Replacement TherapyImmunoglobulin Fc FragmentsHumansChildAdolescentTreatment OutcomeChild, PreschoolJapanMaleFemaleQuality of LifePlain Language Summaries

Stichwörter der Autor:innen

alkaline phosphataseasfotase alfahypophosphatasia

Substanzen

asfotase alfaRecombinant Fusion ProteinsAlkaline PhosphataseImmunoglobulin GImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Department of Genetics & Genomics, College of Medicine & Health Science, United Arab Emirates University, Al Ain, UAE.
  • Genetic Metabolic Division, Department of Pediatric, Tawam Hospital, Al Ain, UAE.
  • Endocrinology Research Centre, Moscow, Russia.

Zitieren

APA

Jasmi, F. A., & Belaya, Z. (2025). Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0227

Vancouver

Jasmi FA, Belaya Z. Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0227

BibTeX
@article{Jasmi2025,
  author = {Jasmi, Fatma Al and Belaya, Zhanna},
  title = {Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0227}
}
Kostenlos starten →